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ABSTRACT
Background    Recent studies revealed that sirtuin 1 
(SIRT1) has a relation to the mechanism of transform-
ing growth factor-beta (TGF-beta) mediated apoptosis in 
glomerular mesangial cells and plays an important role 
in blood pressure regulation. It has been suggested that 
SIRT1 contributes to the renoprotective effect of angio-
tensin receptor blocker (ARB), but this has not yet be-
come clearly recognized. In this study, we examined the 
relationship between SIRT1 and the therapeutic effect of 
olmesartan on renal injury in nephrectomized spontane-
ously hypertensive rats (SHRs). 
Methods    Male Wistar rats and 5/6 nephrectomized 
(5/6Nx) SHRs were assigned to 5 groups as follows: 
group A, Wistar rats; group B, Wistar rats administered 
high-dose olmesartan (15 mg/kg/day); group C, 5/6Nx 
SHRs; group D, 5/6Nx SHRs administered low-dose 
(3 mg/kg/day) olmesartan; and group E, 5/6Nx SHRs 
administered high-dose olmesartan. The drugs were 
administered for 12 weeks. Blood pressure and urinary 
protein excretion were measured every 4 weeks. Serum 
creatinine, glomerular sclerosis, SIRT1 mRNA level, 
TGF-beta mRNA level and klotho mRNA level were 
measured at the end of the examination. 
Results    Systolic blood pressure, urinary protein ex-
cretion, serum creatinine and glomerular sclerosis in 
Wistar rats were significantly lower than that of 5/6Nx 
SHRs. Among 5/6Nx SHRs, high doses of olmesartan 
significantly decreased urinary protein excretion, serum 
creatinine and glomerular sclerosis compared to the 
non-treated and low-dose olmesartan groups. Expression 
of SIRT1 and klotho mRNA were significantly down-
regulated in 5/6Nx SHRs; however, olmesartan did not 
attribute to any change in gene expression. Expression of 
TGF-beta mRNA was significantly increased in 5/6Nx 
SHRs, and olmesartan did not affect the level of TGF-
beta mRNA expression. 
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Conclusion    Expression of SIRT1 is decreased in 
5/6Nx SHRs compared to Wistar rats. Olmesartan sup-
pressed glomerular sclerosis, but did not increase the 
expression of SIRT1, suggesting that the renoprotective 
effect of olmesartan is independent of the SIRT1 path-
way. 
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Recent studies revealed that caloric restriction increases 
the life span of rats and positively affects various diseas-
es such as diabetes, atherosclerosis, neurodegenerative 
diseases, cancer and age-associated renal injury.1 The 
relationship between such favorable effects and caloric 
restriction was found from the observation of budding 
yeast. Guarente and colleagues2 discovered that Sir2 
(silent information regulator 2), the first sirtuin family 
member, increases life span. In mammals, seven homo-
logues of Sir2 [sirtuin 1 (SIRT1) to sirtuin 7] have been 
detected. SIRT1 is mainly expressed in organs such as 
the kidney, liver and brain, and adipose tissue. Expres-
sion of SIRT1 increases with caloric restriction, whereas 
it decreases with senescence. SIRT1 inhibits transform-
ing growth factor-beta (TGF-beta)-induced apoptosis in 
glomerular mesangial cells.3
 There are convincing data that the renin-angiotensin 
system is a major mediator of renal injuries. Blood pres-
sure control using angiotensin receptor blocker (ARB) 
can reduce the progression of nephropathy.4 Several 
studies report that SIRT1 plays an important role in 
blood pressure regulation.5–8 It is considered that SIRT1 
contributes to the renoprotective effect of renin-angio-
tensin system blockade.1
 Angiotensin II participates in various renal lesions 
and ARB has a kidney protective effect. It is reported 
that telmisartan, an angiotensin II type 1 receptor block-
er, increases the expression of SIRT1 mRNA.9 SIRT1 
also may contribute to kidney protection by ARB, but 
this has not yet been clearly proven. 
 In this study, we examined the correlation between 
SIRT1 and the therapeutic effect of olmesartan, another 
ARB on renal injury in nephrectomized spontaneously 
hypertensive rats (SHRs).
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Table 1. Primer sequences
 Forward primer Reverse primer
TGF-beta 5'-CCTGCCCCTACATTTGGA-3' 5'-TGGTTGTAGAGGGCAAGGAC-3'
Sirtuin 1 5'-CAGTGAGAAAATGCTGGCCTA-3' 5'-TTGGTGGTACAAACAGGTATTGA-3'
Klotho 5'-CAAGAAGTTCATAATGGAAAGCTTAAA-3' 5'-ATGCGGTGTACCCAATGAC-3'
Beta-actin 5'-CTGGCTCCTAGCACCATGA-3' 5'-TAGAGCCACCAATCCACACA-3'
TGF-beta, transforming growth factor-beta.
MATERIALS AND METHODS
Animals
Male SHRs of the Izumo strain were obtained from 
Japan SLC (Shizuoka, Japan). As controls, male Wistar 
rats were obtained from Japan SLC. All rats were main-
tained in a room at a controlled temperature of 24 ± 2 ˚C 
with a 12-h light-dark cycle. Animals were given stan-
dard pellet chow and tap water. All experimental proce-
dures were carried out in accordance with the Animal 
Experimentation Guidelines of Tottori University.
Establishment of model
Male 6-week-old SHRs underwent 5/6-nephrectomy. A 
surgical excision of approximately 2/3 of the renal cor-
tex of the left kidney was performed. One week later, the 
right kidney was removed. One week after the surgery 
baseline measurements of body weight, blood pressure, 
urine volume and urinary protein were performed. Blood 
pressure was measured in the conscious state using the 
tail-cuff method with a sphygmomanometer (Softron, 
Tokyo, Japan). Urine was collected from individual rats 
housed in metabolic cages for 24 h. Olmesartan as ARB 
was administered orally once a day using a gastric tube. 
Rats were divided into 5 experimental groups: group A, 
Wistar rats (n = 8); group B, Wistar rats administered 
high-dose olmesartan (15 mg/kg/day, n = 8); group C, 
SHRs (n = 8); group D, SHRs administered low-dose 
olmesartan (3 mg/kg/day, n = 8) and group E, SHRs ad-
ministered high-dose olmesartan (15 mg/kg/day, n = 8). 
Dosages of olmesartan were selected based on previous 
reports.10, 11 The drug was administered once a day for 
12 weeks. Measurements of body weight, blood pres-
sure, urine volume and urinary protein was performed 
every 4 weeks in each group.
 After 12 weeks of drug administration, rats were 
sacrificed under pentobarbital anesthesia. Blood samples 
were obtained prior to death. Serum samples were 
frozen and stored at –80 ˚C, and serum creatinine was 
measured. Remnant kidneys were removed, and a part 
of each kidney sample was fixed in 10% buffered forma-
lin and embedded in paraffin for histological analysis.
RNA extraction and reverse transcription PCR 
analysis
Tissue samples were homogenized and total RNA was 
extracted using an RNasey Mini Kit (Qiagen, Hilden, 
Germany). RNA concentration was determined by mea-
suring absorbance at 260 nm and the RNA quality was 
verified by electrophoresis on an ethidium-bromide-
stained 1% agarose gel. About 2 μg of total RNA was 
reverse transcribed in a final volume of 10 μL containing 
4 μL of 5 × standard buffer, 2 μL of 0.1 M dTT, 1 μL 
of M-MLV reverse transcriptase (Invitrogen, Carlsbad, 
CA), 1 μL of 0.5 μg/μL Random Primer (Promega, Mad-
ison, WI), 1 μL of 20 mM dNTPs and 1 μL of RNase In-
hibitor (Wako Pure Chemical Industries, Osaka, Japan). 
Samples were incubated at 37 ˚C for 60 min, followed by 
95 ˚C for 5 min and cooling to 4 ˚C for 5 min.
Real-time PCR
For quantitative real-time PCR, we used 10 μL of re-
verse transcribed samples: EXPRESS qPCR Super mix 
Premixed ROX (Invitrogen), 5 μL; forward primer (10 
μM), 0.9 μL; reverse primer (10 μM), 0.9 μL; a TaqMan 
Probe (2 μM), 1.2 μL (Roche) and a cDNA sample, 2 
μL. mRNA levels of TGF-beta, SIRT1 and klotho were 
assessed by real-time PCR assays using beta-actin as 
a housekeeping gene. The forward and reverse primer 
sequences used for this study are shown in Table 1. The 
thermal cycler conditions were as follows: hold at 95 ˚C 
for 30 s and 60 ˚C for 1 min.
Histological analysis
Three-micrometer sections of formalin-fixed, paraffin-
embedded kidney samples were stained with periodic 
acid-Schiff and periodic acid-methenamine silver. To 
calculate focal glomerular sclerosis, 100 to 150 glom-
eruli from each stained specimen were examined. The 
degree of sclerosis in each glomerulus was subjectively 
graded on a scale of 0 to 4 as follows: Grade 0, no 
change; Grade 1, sclerotic area less than or equal to 1/4 
of the glomerulus or the presence of distinct adhesion 
between the capillary tuft and Bowman’s capsule; Grade 
2, sclerosis of 1/4 to 1/2 of the total glomerular area; 
Grade 3, sclerosis of 1/2 to 3/4 of the total glomerular 
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area; and Grade 4, sclerosis of more than 3/4 of the 
glomerulus. The index of glomerular sclerosis (IGS) was 
calculated by using the following formula as previously 
reported10: 
       IGS = (1 × N1) + (2 × N2) + (3 × N3) + (4 × N4)
 
 (N0 + N1 + N2 + N3 + N4)
where N is the number of glomeruli at each grade of 
sclerosis.
Statistical analysis
Statistical significance of intergroup differences in quan-
titative data was assessed by Student’s t-test (StatFlex 
version 6 for Windows, Artec, Osaka, Japan). P < 0.05 
was considered significant. 
RESULTS 
Blood pressure
The systolic and diastolic blood pressure in the rats dur-
ing the 12-week experimental period is shown in Fig. 1. 
The systolic blood pressure was higher in 5/6Nx SHRs 
than in Wistar rats during the 12-week experimental 
period. The systolic pressure increased throughout the 
experimental period in the nephrectomized group (group 
C). At week 12, olmesartan decreased systolic blood 
pressure dose dependently (groups D and E) (P < 0.01). 
However, there was no significant difference in systolic 
blood pressure between the high-dose olmesartan group 
(group E) and low-dose group (group D) at week 4 and 
week 8. There was a similar trend for diastolic pressure 
(data not shown). 
Fig. 2. Urinary protein excretion and serum creatinine.
 A: Urinary protein excretions are lower in the Wistar rats than 
in the SHRs. Among SHRs, the high-dose olmesartan group 
show lower urinary protein excretion. 
 B: The serum creatinine levels are significantly higher in the 
SHRs than in the Wistar rats. Among SHRs, the high-dose 
olmesartan group show lower serum creatinine, while there 
is no difference between the low-dose group and non-treated 
group. 
 **P < 0.01, *** P < 0.001. Abbreviations, refer to the legends of 
Fig. 1.
Fig. 1. Systolic blood pressure during the experimental period. 
The systolic blood pressure is higher in SHRs than in Wistar rats. 
At week 12, olmesartan significantly decreased the systolic blood 
pressure dose dependently (P < 0.01). Low OLM, olmesartan 3 
mg/kg/day; High OLM, olmesartan 15 mg/kg/day; 5/6Nx SHR, 
5/6 nephrectomized spontaneously hypertensive rat. 
Proteinuria
Figure 2A shows total urinary protein excretion in each 
group at the end of the examination. Urinary protein lev-
els were lower in the Wistar rats (groups A and B) than 
SHRs (groups C, D and E). Among SHRs, those treated 
with high-dose olmesartan (group E) showed lower uri-
nary protein excretion. 
Serum creatinine
Figure 2B shows serum creatinine in each group at week 
12. The serum creatinine levels were significantly higher 
in SHRs than Wistar rats. Among SHRs, those treated 
with high-dose olmesartan (group E) showed lower se-
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Grade 0
 No change
Grade 1
 Sclerosis of  
less than or equal 
to 1/4 of the glom-
erulus or the pres-
ence of distinct 
adhesion between 
the capillary tuft 
and Bowman’s 
capsule
Grade 2
 Sclerosis of  
1/4–1/2 of the total 
glomerular area
Grade 3
 Sclerosis of 
1/2–3/4 of the total 
glomerular area
Grade 4
 Sclerosis of  
more than 3/4 of 
the glomerulus
rum creatinine, while there was no difference between 
those treated with low-dose olmesartan (group D) and 
non-treated rats (group C).
Histological findings in the kidney
Figure 3 shows the IGS in each group. In the Wistar rats 
(groups A and B), only a few sclerotic changes of glom-
eruli and interstitial fibrosis were observed. The value of 
the index treated with high-dose olmesartan group (group 
E) was significantly lower than that of low-dose olmes-
artan group (group D) and non-treated group (group C), 
respectively. 
mRNA quantification of TGF-beta, SIRT1 and 
klotho
The SIRT1 mRNA level in the nephrectomized rats 
was significantly decreased when compared with that 
in the Wistar rats. Administration of olmesartan did not 
change in the level of SIRT1 expression among SHRs 
(Fig. 4A). The level of TGF-beta mRNA expression in 
the non-treated SHRs (group C) was significantly higher 
than the Wistar rats (groups A and B). Olmesartan did 
not affect the level of TGF-beta mRNA expression 
among each group (Fig. 4B). The klotho mRNA level 
in the nephrectomized rats was significantly lower than 
that in the Wistar rats, and olmesartan did not affect the 
level of klotho mRNA expression (Fig. 4C).
Fig. 3. Index of glomerular sclerosis (IGS).
 A: Classification of glomerular sclerosis by periodic acid-Schiff 
stain. Bar = 200 µm.
 B: The values of the index in the high-dose olmesartan groups 
are significantly lower than those in the low-dose groups and 
non-treated groups. ***P < 0.001. Abbreviations, refer to the 
legends of Fig. 1.
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         N, the number of glomeruli at each grade of sclerosis.
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Fig. 4. Levels of mRNA for sirtuin 1 (SIRT1), transforming 
growth factor (TGF)-beta and klotho gene expression in renal tis-
sue. The levels were standardized using the beta-actin level. 
 A: SIRT1 mRNA levels in the SHRs are significantly decreased 
than in the Wistar rats. Among SHRs, olmesartan does not 
attribute to any change in the level of SIRT1 mRNA expres-
sion. 
 B: Levels of TGF-beta mRNA expression in the SHRs are 
significantly higher than in the Wistar rats. Among SHRs, 
olmesartan does not affect the level of TGF-beta mRNA ex-
pression. 
 C: Levels of klotho mRNA expression in the SHRs are signifi-
cantly lower than in the Wistar rats. Among SHRs, olmesar-
tan does not affect the level of klotho mRNA expression. 
*P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations, refer to the 
legends of Fig. 1.
DISCUSSION
In the present study, olmesartan decreased proteinuria 
and ameliorate histological renal damage in SHRs. 
SIRT1 expression in the kidney decreased in SHRs com-
pared to normotensive Wistar rats, and olmesartan did 
not increase SIRT1 expression in the kidneys of SHRs.
 SHRs have been used as a model for essential hy-
pertension in humans, and 5/6Nx rats have commonly 
been used as an experimental models for chronic renal 
failure in humans.10 In the present study, we combined 
these two models, and prepared 5/6Nx SHRs. During 
the 12-week experimental period, blood pressure, uri-
nary protein and glomerular sclerosis in the 5/6Nx SHRs 
increased progressively. After 12 weeks, the glomerular 
sclerosis was remarkable. 
 Expression of SIRT1 increases with caloric restric-
tion and in conditions that cause oxidative stress and 
DNA damage,12, 13 while it decreases with a high fat diet, 
insulin resistance, high glucose and senescence.1 In the 
kidney, SIRT1 acts as a renal survival factor by confer-
ring resistance to cellular stress such as hypoxia, reduc-
ing interstitial fibrosis, inhibiting tubular and glomerular 
cell apoptosis and inflammation and regulating sodium 
handling, blood pressure and renal lipid metabolism.5 In 
the present study, the expression of SIRT1 in the kidney 
was decreased in SHRs compared to Wistar rats. In a 
previous study, however, the expression of SIRT1 was 
increased in the heart of SHRs.14
 The renin-angiotensin system plays an important 
role in the development of renal injury. There are con-
vincing data that the renin-angiotensin system is a major 
mediator of renal injuries. Angiotensin II induces the 
generation of cytotoxic products such as superoxide 
and hydrogen peroxide via angiotensin type 1 receptor 
stimulation. Olmesartan and other ARBs reduce oxida-
tive stress.15, 16 In addition to the effect on glomerular 
hypertension, ARBs are effective in reducing interstitial 
fibrosis and tubular atrophy, each of which is closely 
correlated to progressive renal dysfunction. In the pres-
ent study, olmesartan showed an effect in decreasing 
blood pressure and preventing glomerular sclerosis. Fan 
et al. reported that ultrahigh doses of olmesartan showed 
greater renoprotective effects, and that efficacy was in-
dependent of blood pressure.11
 Miyazaki reported that overexpression of SIRT1 in 
vascular smooth muscle cells or treatment with resvera-
trol, an activator of SITR1, suppressed angiotensin type 
1 receptor expression.6 In the present study, however, 
olmesartan did not show any effect on the expression of 
SIRT1 in both SHRs and Wistar rats. Shiota et al. re-
ported that telmisartan, an angiotensin II type 1 receptor 
blocker, increased the expression of SITR1 in the skel-
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etal muscle of obese smice.9 Telmisartan acts as a per-
oxisome proliferator-activated receptor (PPAR)-gamma 
activator.17 Elena suggested that PPARs participate in 
the retardation of aging mediated by angiotensin II in-
hibition.18 Imayama showed that telmisartan suppressed 
angiotensin II type 1 receptor expression through the 
PPAR-gamma mediated pathway.19 It is supposed that 
the renoprotective effect of olmesartan is related to 
blood pressure regulation and oxidative stress, and that 
this effect is independent of SIRT1 pathway. 
 Klotho is known as a circulating hormone that re-
presses the intracellular signals of insulin and insulin-
like growth factor 1 and acts as an aging-suppressor.18 
Downregulation of the klotho gene in the kidney has 
been reported in SHRs, and in an experimental study, 
olmesartan prevented klotho downregulation resulting in 
a renoprotective effect.20 In the present study, however, 
olmesartan did not show any effect on klotho mRNA 
expression in SHR groups. 
 In conclusion, olmesartan suppressed glomerular 
sclerosis, but did not increase the expression of SIRT1, 
suggesting that the renoprotective effect of olmesartan is 
independent of the SIRT1 pathway. Further studies are 
required to investigate the correlation between angioten-
sin and sirtuins. 
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